Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1118)	11/14/2001 1:45:50 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

No, not at all. the dramatic improvements in treatment of RA and other chronic inflammatory diseases only indicate how lousy therapy was. There is still lots of room for improvement. That said, I always thought that it would take a cocktail of anti-TNF, anti-IL-1, anti-complement, etc. to demo significant protection. I have been amazed at the efficacy of anti-TNF therapy as a stand alone. Kineret? Not as impressive as anti-TNF therapies, IMO. Amgen knows how to conduct large trials to get approval for marginal advances.